Following publication of the original article [1], the authors reported formal errors in the Figs. 1, 2, 3, 4 and 5. The axis labeling was inconsistent and figures were in low resolution. Also, reference #6 (Günther R, Wurster CD, Cordts I, Koch JC, Kamm C, Petzold D, et al. Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy. Front Neurol. 2019;10:1098. https://doi.org/10.3389/fneur.2019.01098) was incomplete and lacked DOI. The correct figures are presented below. Comparison of ECAS absolute outcome scores of patients with SMA type 2 and 3 before treatment initiation (V0) A, B, C: Box plots of the ALS-specific domains in patients with SMA type 2 compared to patients with SMA type 3. D, E: Box plots of the non-ALS-specific domains in patients with SMA type 2 compared to patients with SMA type 3. F, G: Box plots of ECAS subscores in patients with SMA type 2 compared to patients with SMA type 3. H: Boxplot of ECAS total score in patients with SMA type 2 compared to patients with SMA type 3. ALS: amyotrophic lateral sclerosis; ECAS: Edinburgh Cognitive and Behavioral ALS Screen; SMA: spinal muscular atrophy. Box plots show median (horizontal line), inter-quartile range (boxes) and scores outside of inter-quartile range (whiskers). Calculated by Mann–Whitney U-test. Significance levels: ** p < 0.01; ns: statistically not significant Comparison of ECAS absolute scores before and after treatment initiation A, B, C: Box plots of the ALS-specific domains before and after treatment initiation with nusinersen in SMA cohort. D, E: Box plots of the non-ALS-specific domains before and after treatment initiation with nusinersen in SMA cohort. F, G: Box plots of ECAS subscores before and after treatment initiation with nusinersen in SMA cohort. H: Box plots of ECAS total score before and after treatment initiation with nusinersen in SMA cohort. ALS: Amyotrophic lateral sclerosis; ECAS: Edinburgh Cognitive and Behavioral ALS Screen; SMA: Spinal muscular atrophy. V0: Baseline visit before treatment initiation; V1: Follow-up visit 14 months after treatment initiation. Box plots show median (horizontal line), inter-quartile range (boxes) and scores outside of inter-quartile range (whiskers). Calculated by Wilcoxon signed-rank test. Significance levels: * p < 0.05; ** p < 0.01; *** p < 0.001; ns: statistically not significant Spaghetti plots for longitudinal changes in ECAS of SMA cohort Spaghetti plots for A: ALS-specific subscore, B: non-ALS-specific subscore, C: ECAS total score. ALS: amyotrophic lateral sclerosis; ECAS: Edinburgh Cognitive and Behavioral ALS Screen; SMA: spinal muscular atrophy. V0: Baseline visit before treatment initiation; V1: Follow-up visit 14 months after treatment initiation. Each line represents an individual patient Comparison of motor outcome scores before and after treatment initiation A, B, C: Box plots of the motor outcome scores before and after treatment initiation with nusinersen in SMA cohort. ALSFRS-R: ALS Functional Rating Scale Revised; HFMSE: Hammersmith Functional Motor Scale Expanded; RULM: Revised Upper Limb Module; SMA: Spinal muscular atrophy V0: Baseline visit before treatment initiation; V1: Follow-up visit 14 months after treatment initiation. Box plots show median (horizontal line), inter-quartile range (boxes) and scores outside of inter-quartile range (whiskers). Calculated by Wilcoxon signed-rank test. Significance levels: * p < 0.05; ** p < 0.01; ns: statistically not significant Comparison of ECAS total scores between SMA type 2/3 patients with improvement (score change > 0) and without improvement (score change ≤ 0) in motor outcome scores. ALSFRS-R: ALS Functional Rating Scale Revised; ECAS: Edinburgh Cognitive and Behavioral ALS Screen; HFMSE: Hammersmith Functional Motor Scale Expanded; RULM: Revised Upper Limb Module; ns: statistically not significant; Box plots show median (horizontal line), inter-quartile range (boxes) and scores outside of inter-quartile range (whiskers). Calculated by Mann–Whitney U-test The original article [1] has been updated.